Wuxi Biologics has reported a full-year net income of 3.40 billion yuan, falling short of the estimated 3.58 billion yuan. The company’s revenue exceeded estimates, coming in at 17.03 billion yuan against an estimated 16.98 billion yuan. Adjusted net income surpassed estimates, with Wuxi Biologics reporting 4.70 billion yuan against an estimated 4.2 billion yuan. The gross margin for the c...
药明康德股票讨论区
JUST IN:
NBS:
Revenue growth at industrial enterprises picked up markedly as market demand continued to recover and industrial output expanded rapidly, which created favorable conditions for their profits.
Some 29 out of China's 41 main industries saw profits rise in the first two months.
$阿里巴巴(BABA.US)$$阿里巴巴-SW(09988.HK)$$腾讯控股(00700.HK)$$小米集团-W(01810.HK)$$京东集团-SW(09618.HK)$$百度集团-SW(09888.HK)$$比亚迪股份(01211.HK)$$商汤-W(00020.HK)$$中国石化(600028.SH)$
Wuxi Biologics Earnings Report: FY Net Income Misses Estimates Despite Revenue Surpassing Predictions
The company’s revenue exceeded estimates, coming in at 17.03 billion yuan against an estimated 16.98 billion yuan.
Adjusted net income surpassed estimates, with Wuxi Biologics reporting 4.70 billion yuan against an estimated 4.2 billion yuan.
The gross margin for the c...
暂无评论